Jakob Mosegaard Larsen

Board member at Forward Pharma

Mr. Larsen has served on our board of directors since July 2015. Mr. Larsen is currently a partner at Copenhagen-based law firm Mazanti-Andersen Korsø Jensen Law Firm LLP. Prior to January 1, 2016, Mr. Larsen was a Partner at Copenhagen-based the law firm Nielsen Nørager Law Firm LLP. Mr. Larsen serves as a trusted advisor of Danish and international private equity and venture fund managers. He has several years of experience acting as a legal adviser of biotech and life science companies. Mr. Larsen is chairman of the Danish Venture Capital and Private Equity Association’s (DVCA) Legal Committee and serves as DVCA’s representative on Invest Europe’s Legal and Regulatory Committee. He graduated from Copenhagen University with a Master’s Degree in Law and holds an executive MBA from Copenhagen Business School. Mr. Larsen and Mazanti-Andersen Korsø Jensen LLP act as Danish legal counsel to the Company and the Nordic Biotech funds that currently are shareholders of the Company. Mr. Larsen is also a member of the board of directors of the advisory company of two of the Nordic Biotech funds that currently are shareholders of the Company.


Org chart

This person is not in the org chart


Teams

This person is not in any teams


Offices

This person is not in any offices


Forward Pharma

1 followers

Forward Pharma A/S is a Danish biopharmaceutical company that commenced development in 2005 of a proprietary formulation of DMF for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The Company has the opportunity to receive royalties from Biogen on Biogen’s net sales of Tecfidera® or other DMF products for multiple sclerosis outside the U.S., dependent on, among other things, a favorable outcome in Europe with respect to the ‘355 Patent Opposition Proceeding, including any appeal thereto.


Industries

Employees

1-10

Links